Latest News

Paris and New York. – In a peer-reviewed study published today in Nature Communications, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing...
As any parent can attest, there are endless scenarios involving young children that can cause many a sleepless night. But one scenario involving Jon and Lisa Loomer’s son, Michael, could not have been more unexpected. The Loomers took Michael to the doctor after he started experiencing some breathing problems in...
Hopes that a malaria vaccine could be widely available by 2012 have risen with the start last week (26 May) of phase III trials of the world’s most advanced candidate. Five infants in Bagamoyo, Tanzania, have received GlaxoSmithKline’s RTS,S vaccine and 16,000 children aged two and under will receive the...
Salt Lake City, Utah – Doctors diagnosed Christopher Gregg, Ph.D., member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah and neuroscientist and professor of neurobiology and human genetics at the at the same institution, with stage 4 metastatic breast...
DUBLIN – Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society (ERS), which include use of Acthar® Gel (repository corticotropin injection) therapy in the clinical management of certain patients with pulmonary sarcoidosis, published in European Respiratory Journal.[1] The treatment...
DUBLIN, Ireland — Mallinckrodt plc, a global specialty pharmaceutical company, recently announced the publication of findings from a cost analysis of TERLIVAZ® (terlipressin) for injection for adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.This analysis assessed the treatment-related cost per patient response with TERLIVAZ plus albumin from...
DUBLIN, March 4, 2021 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safety of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure...
CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis — DUBLIN – Mallinckrodt Plc, a global biopharmaceutical company, today announced the publication of results from its pivotal Phase 3 CONFIRM...